Pub. Date : 2021 Mar 25
PMID : 33067614
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | This Phase I study investigated the recommended Phase II dose (RP2D) of inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with multiple-relapsed/refractory (R/R) CD22-positive acute lymphoblastic leukemia (ALL). | OZOGAMICIN | CD22 molecule | Homo sapiens |